flortaucipir F 18 (Rx)

Brand and Other Names:Tauvid
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 300-1,900 MBq/mL (8.1-51 mCi/mL) in 30 mL multidose vials
  • At time of administration, 370 MBq (10 mCi) are contained in up to 10 mL solution for injection

Tau Neurofibrillary Tangles Estimation

Indicated for use with positron-emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adults with cognitive impairment who are being evaluated for Alzheimer disease (AD)

370 MBq (10 mCi) IV bolus in a total volume of ≤10 mL

Image acquisition

  • Starting ~80 min after IV bolus, obtain a 20-min PET image with the patient supine
  • Position head to center the brain (including the cerebellum) in the PET scanner field of view
  • Tape or other flexible head restraints may be used to reduce head movement

Image display

  • Display images in the transverse, sagittal, and coronal planes
  • Reorient images to remove head tilt in the transverse and coronal plane
  • Use a sagittal slice just off the midline to align the inferior frontal and inferior occipital poles in the horizontal plane

Image interpretation

  • Interpret imaging independently of the patient’s clinical features and other imaging
  • Interpret images based on the pattern and density of the radioactive signal within the neocortical gray matter (not within white matter or in regions outside of the brain)
  • Only uptake of tracer in the neocortical grey matter regions should contribute to scan interpretation
  • Off-target binding may be seen in the choroid plexus, striatum, and brainstem nuclei
  • Small foci of noncontiguous tracer uptake may lead to false-positive interpretation
  • Interpret scans that have isolated or noncontiguous, small foci in any region with caution
  • See prescribing information for additional information
  • Positive scan
    • Scan shows increased neocortical activity in posterolateral temporal (PLT), occipital, or parietal/precuneus region(s), with or without frontal activity
  • Negative scan
    • Scan shows no increased neocortical activity, or shows increased neocortical activity isolated to the mesial temporal, anterolateral temporal, and/or frontal regions

Dosing Considerations

Assess pregnancy status in females of reproductive potential before administration

Limitation of use

  • Not for use in the evaluation of patients for chronic traumatic encephalopathy (CTE)

Safety and efficacy not established

Next:

Adverse Effects

1-10%

Headache (1.4%)

Injection site pain (1.2%)

<1%

Increased blood pressure (0.8%)

Previous
Next:

Warnings

Contraindications

None

Cautions

Safety and efficacy not established for patients being evaluated for CTE

Risk for misdiagnosis

  • Imaging agent does not target beta-amyloid, 1 of 2 required components of the neuropathological diagnosis of AD
  • Performance for detecting tau pathology was assessed in terminally ill patients, the majority of whom had AD dementia with B3 level NFT pathology
  • Performance for detecting tau pathology may be lower in patients in earlier stages of the pathological spectrum
  • Negative scan
    • NFTs may be present at levels that qualify for neuropathological diagnosis of AD (B2 tau pathology in presence of at least moderate levels of cortical amyloid pathology)
    • Consider additional evaluation to confirm absence of AD pathology
  • False-positive scan
    • Small foci of noncontiguous tracer uptake may lead to a false-positive scan
    • Only uptake of tracer in neocortex should contribute to interpretation of a positive scan

Radiation risk

  • Diagnostic radiopharmaceuticals expose patients to radiation
  • Radiation exposure is associated with a dose-dependent increased risk of cancer
  • Ensure safe handling and preparation procedures to protect patients and health-care workers from unintentional radiation exposure
Previous
Next:

Pregnancy & Lactation

Pregnancy

All radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose

Advise pregnant females of potential risks of fetal exposure to radiation

Not likely to be used in females of reproductive age

No data available use in pregnant females

Lactation

There are no data on the presence of flortaucipir F 18 in human milk, or its effects on breastfed infants or milk production

Advise a lactating females to avoid breastfeeding for 4 hr after administration in order to minimize radiation exposure to a breastfed infant

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Flortaucipir F 18 binds to aggregated tau protein

In brains of patients with AD, tau aggregates combine to form NFTs, 1 of 2 components required for neuropathological diagnosis of AD

Distribution

Distributed throughout the body with <10% of the injected flortaucipir F 18 radioactivity present in the blood by 5 min following administration, and <5% present in the blood by 10 min after administration

Elimination

Clearance: Primarily by hepatobiliary and renal excretion

Previous
Next:

Administration

IV Preparation

Radioactive drug

Only authorized persons qualified by training and experience should receive, use, or administer injection

Use aseptic technique and radiation shielding during preparation and administration

Visually inspect solution before administration; do not use it if it contains particulate matter or if it is discolored (solution appears clear and colorless)

Dilute aseptically with 0.9% NaCl to a maximum dilution of 1:5 by the end-user

Use diluted product within 3 hr of dilution and prior to product expiration

Assay dose in a suitable dose calibrator before administration

IV Administration

Follow injection with IV flush of 0.9% NaCl

Dispose of any unused drug in compliance with applicable regulations

Storage

Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF)

Does not contain a preservative

Store upright in a shielding container

Expiration date and time are provided on the container label

Use within the labeled expiration

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.